Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-DOTA-PLMIKRSKK
- Development stage
- Unknown
- Lead developer
- Bhabha Atomic Research Centre
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
01
Overview
[177Lu]Lu-DOTA-PLMIKRSKK: sourced facts only. name: "Amongst the three radiopeptides, [177Lu]Lu-DOTA-PLMIKRSKK exhibited significantly reduced cellular uptake (95% inhibition) during blocking studies in SKOV3 cells (ER-, PR- and GPER+) than in MCF7 (ER+, PR+ and GPER+) cells (80%) indicating high GPER-specificity." [PMID:42612457]; target: "Amongst the three radiopeptides, [177Lu]Lu-DOTA-PLMIKRSKK exhibited significantly reduced cellular uptake (95% inhibition) during blocking studies in SKOV3 cells (ER-, PR- and GPER+) than in MCF7 (ER+, PR+ and GPER+) cells (80%) indicating high GPER-specificity." [PMID:42612457]; developer: "Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India." [PMID:42612457]; modality: "The three peptides: DOTA-PLMI, DOTA-PLMIKRSKK and DOTA-KRSKKPLMI were radiolabeled with lutetium-177." [PMID:42612457]
Beyond the preview
Go deeper on [177Lu]Lu-DOTA-PLMIKRSKK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-DOTA-PLMIKRSKK.